Antisense Therapeutics Limited (ASX:ANP) has announced that it intends to conduct a double-blind, placebo-controlled six-month dosing trial of ATL1102 followed by a six-month open-label phase 2b trial in non-ambulant boys with Duchenne’s Muscular Dystrophy. …
Antisense Therapeutics announces revised clinical development plan for ATL1102
September 8, 2022 Australian Biotech
Latest Video
New Stories
-
NSW pharmacists to deliver all childhood vaccines and treat more conditions under reforms
September 11, 2026 - - Latest News -
Rare genetic motor neurone disease treatment finally reaches Australian patients
September 11, 2026 - - Latest News -
Taking a stake is not the same as spectating investor risk and expecting a benefit
September 10, 2026 - - Latest News -
Artificial intelligence in HTA has arrived, kind of, but nobody was thinking of this
September 10, 2026 - - Latest News -
Melbourne oncologist takes the reins at Australia's private cancer physicians body
September 10, 2026 - -
Australia secures sovereign viral vector manufacturing as VVMF wins TGA licence
September 10, 2026 - - Latest News -
Which is it? The two perspectives on patient input compounded by the lack of transparency
September 10, 2026 - - Latest News